Tumor necrosis factor-alpha and mortality in heart failure: a community study
- PMID: 18645056
- PMCID: PMC2682349
- DOI: 10.1161/CIRCULATIONAHA.107.759191
Tumor necrosis factor-alpha and mortality in heart failure: a community study
Abstract
Background: Tumor necrosis factor-alpha (TNFalpha), an inflammatory cytokine, was reported to be elevated in trials of heart failure (HF) with reduced ejection fraction (EF) and associated with mortality. Whether this is true for HF with preserved EF is unknown, and community data are lacking. We evaluated the distribution of TNFalpha, its association with baseline characteristics and mortality, and its benefit in assessing risk in community HF patients.
Methods and results: Olmsted County residents with active HF from July 2004 to March 2007 (n=486; mean age, 76.7 years; EF > or =50%, 55%) were prospectively recruited. Clinical characteristics and TNFalpha were measured. Elevated TNFalpha (more than the assay limit of normal of 2.8 pg/mL) was present in 143 (29%). Higher TNFalpha was associated with decreased creatinine clearance, nonsmoking status, anemia, and greater comorbidity (P(trend)<0.05 for all). Mortality increased with increasing TNFalpha (P=0.016), with 1-year mortality estimates of 16%, 18%, 23%, and 32% from the lowest to highest quartile, respectively. After adjustment for age, sex, and EF, the hazard ratios for death were 1.24, 1.37, and 1.90 from the second to the highest TNFalpha quartile, respectively (P(trend)=0.007). TNFalpha contributed to risk assessment as indicated by increases in the area under the receiver operating characteristic curves in all models examined (P<0.05 for all). Results did not differ by EF (P=0.60 interaction term of TNFalpha and EF).
Conclusions: TNFalpha was elevated in a large portion of community HF patients, was associated with a large decrease in survival, and provided a significant incremental increase in risk assessment above established indicators. TNFalpha is useful for risk assessment in HF patients with preserved and reduced EF.
Figures
Similar articles
-
Mortality Associated With Heart Failure After Myocardial Infarction: A Contemporary Community Perspective.Circ Heart Fail. 2016 Jan;9(1):e002460. doi: 10.1161/CIRCHEARTFAILURE.115.002460. Epub 2015 Dec 23. Circ Heart Fail. 2016. PMID: 26699392 Free PMC article.
-
Inflammatory pathways in patients with heart failure and preserved ejection fraction.Int J Cardiol. 2008 Sep 16;129(1):111-7. doi: 10.1016/j.ijcard.2007.05.061. Epub 2007 Jul 20. Int J Cardiol. 2008. PMID: 17658631
-
Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer.Circulation. 2017 Apr 11;135(15):1388-1396. doi: 10.1161/CIRCULATIONAHA.116.025434. Epub 2017 Jan 29. Circulation. 2017. PMID: 28132957 Free PMC article.
-
Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction.J Am Heart Assoc. 2018 Oct 16;7(20):e009594. doi: 10.1161/JAHA.118.009594. J Am Heart Assoc. 2018. PMID: 30371285 Free PMC article.
-
Atherosclerotic Burden and Heart Failure After Myocardial Infarction.JAMA Cardiol. 2016 May 1;1(2):156-62. doi: 10.1001/jamacardio.2016.0074. JAMA Cardiol. 2016. PMID: 27437886 Free PMC article.
Cited by
-
Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments.Bioengineering (Basel). 2024 Jan 1;11(1):45. doi: 10.3390/bioengineering11010045. Bioengineering (Basel). 2024. PMID: 38247923 Free PMC article. Review.
-
Inflammation in Heart Failure-Future Perspectives.J Clin Med. 2023 Dec 17;12(24):7738. doi: 10.3390/jcm12247738. J Clin Med. 2023. PMID: 38137807 Free PMC article. Review.
-
Plasma tumour necrosis factor-alpha-related proteins in prognosis of heart failure with pulmonary hypertension.ESC Heart Fail. 2023 Dec;10(6):3582-3591. doi: 10.1002/ehf2.14507. Epub 2023 Sep 29. ESC Heart Fail. 2023. PMID: 37772417 Free PMC article.
-
A comprehensive review of acute cardio-renal syndrome: need for novel biomarkers.Front Pharmacol. 2023 May 23;14:1152055. doi: 10.3389/fphar.2023.1152055. eCollection 2023. Front Pharmacol. 2023. PMID: 37288107 Free PMC article. Review.
-
New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back.Biomedicines. 2022 Dec 27;11(1):70. doi: 10.3390/biomedicines11010070. Biomedicines. 2022. PMID: 36672578 Free PMC article. Review.
References
-
- Torre-Amione G. Immune activation in chronic heart failure. American Journal of Cardiology. 2005;95(suppl):3C–8C. - PubMed
-
- Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation. 2006;113:e72–e75. - PubMed
-
- Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New England Journal of Medicine. 1990;323:236–41. - PubMed
-
- Deswal A, Peterson NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the vesnarinone trial (VEST) Circulation. 2001;103:2055–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
